Targeting CLPB conquers venetoclax resistance regulated by p53 loss and renders acute myeloid leukemia (AML) cells sensitive to the co-treatment with Venetoclax and Azacitidine through the induction of pro-apoptotic proteins (80). The gene discussed is TP53; the disease is acute myeloid leukemia.